BusinessIGC to Distribute its Formulations in Germany in Early 2018By Nasdaq OMXOct 25, 2017, 12:00 PM UTC
BusinessIGC Prepares a Liquid Delivery Formulation of IGC-AD1 for Alzheimer’s Based on Novel In Vitro DataBy Nasdaq OMXOct 4, 2017, 12:00 PM UTC
BusinessIGC Readies Line of Medical Dispensary Products Targeting Alzheimer’s Disease Based on Novel DataBy Nasdaq OMXSep 18, 2017, 12:01 PM UTC
BusinessIGC’s Drug Candidate for Alzheimer’s Potentially Presents New Molecular Pathway for THC to Inhibit Aβ40 ProductionBy Nasdaq OMXSep 11, 2017, 12:00 PM UTC
BusinessIGC’s CEO and Key Scientific Advisor Quoted in “HIGH TIMES” Article on THC and Alzheimer’s DiseaseBy Nasdaq OMXAug 3, 2017, 10:06 AM UTC
BusinessIGC Builds Team Adding Industry Leader Dr. Chuanhai Cao, an expert on THC-Based Alzheimer’s Disease TreatmentsBy Nasdaq OMXAug 1, 2017, 12:42 PM UTC
